Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05769920 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation TTHX1114 Ophthalmic Solution
A Phase 1 study of Corneal Epithelial Degeneration, sponsored by Trefoil Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT05769920: Completed Phase 1 study of Corneal Epithelial Degeneration, sponsored by Trefoil Therapeutics.
NCT05769920 is a Phase 1 study of Corneal Epithelial Degeneration that has completed, run by Trefoil Therapeutics. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05769920, a Phase 1 study of Corneal Epithelial Degeneration, has completed, sponsored by Trefoil Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Dose escalation 3+3 design with accelerated titration 4 dose levels
Primary Outcome
Important Medical Events (ocular) related to study treatment
Conditions Studied
Interventions
- DRUG TTHX1114(NM141) Ophthalmic Solution
Study Locations (1)
California
- Trefoil Clinical Site #132 - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-12-06 |
| Est. Completion | 2023-04-12 |
| Phase | Phase 1 |
What the finished NCT05769920 record still lists
NCT05769920 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Corneal Epithelial Degeneration appearing as the primary indexed condition, and to 1 intervention - of which TTHX1114(NM141) Ophthalmic Solution is the first listed.
NCT05769920 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05769920 about?
NCT05769920 is a clinical study titled "Dose Escalation TTHX1114 Ophthalmic Solution". Dose escalation 3+3 design with accelerated titration 4 dose levels
What is the current status of trial NCT05769920?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2022-12-06. Estimated completion is 2023-04-12.
What conditions does trial NCT05769920 study?
This clinical trial studies the following conditions: Corneal Epithelial Degeneration.
What interventions are being tested in trial NCT05769920?
The interventions under investigation include: TTHX1114(NM141) Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT05769920?
This trial is sponsored by Trefoil Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05769920 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05769920's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI